Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Buffalo, New York 14263


Purpose:

This phase II clinical trial is studying how well lenalidomide works in treating patients with high-risk chronic lymphocytic leukemia. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing.


Study summary:

PRIMARY OBJECTIVES: I. To determine the time to progression in patients with high-risk chronic lymphocytic leukemia (CLL) treated with lenalidomide. SECONDARY OBJECTIVES: I. To determine the clinical response (complete and partial response) in treatment-naïve patients with high-risk CLL treated with single-agent lenalidomide. II. To determine the incidence of immune-mediated flare reaction. III. To determine the toxicity profile of single-agent lenalidomide in previously untreated patients with high-risk CLL. IV. To conduct correlative studies in bone marrow, peripheral blood, and/or lymph nodes of patients treated with lenalidomide. OUTLINE: Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses. Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for correlative studies. After completion of study therapy, patients are followed up every 3 months for a maximum of 5 years.


Criteria:

Inclusion Criteria: - Definitive diagnosis of B-cell chronic lymphocytic leukemia (B-CLL) as defined by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria - Must have high-risk B-CLL as defined by ≥ one of the following: - High-risk cytogenetics (either 17p deletion and/or 11q deletion) - Unmutated immunoglobulin heavy chain gene rearrangement - Zap-70 and CD38 expression on leukemic cells will not be used as eligibility criteria for enrollment into the clinical trial - No prior treatment for the management of B-CLL - Patients must have B-CLL requiring therapy as defined by the IWCLL criteria - Must have measurable disease meeting one of the following criteria: - Absolute lymphocyte count > 5,000/μL - Measurable lymphadenopathy or organomegaly - No tumor lysis syndrome (TLS) by Cairo-Bishop definition - Patients with correction of electrolyte abnormalities allowed - ECOG performance status 0-2 - ANC ≥ 1,500/mm³ - Platelet count ≥ 75,000/mm³ - Creatinine clearance ≥ 30 mL/min - Total bilirubin ≤ 1.5 times upper limit of normal (ULN) - AST and ALT ≤ 3 times ULN (≤ 5 times ULN if hepatic metastases are present) - Uric acid normal - Patients with elevated uric acid allowed provided it is corrected with appropriate pharmacologic measures - Not pregnant or nursing - Negative pregnancy test - Fertile patients must commit to continued abstinence from heterosexual intercourse or use 2 acceptable methods of contraception (1 highly effective method and 1 additional effective method) ≥ 28 days prior to, during, and for ≥ 28 days after discontinuing lenalidomide - Able to adhere to the study visit schedule and other protocol requirements - No serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the informed consent form - No condition, including the presence of laboratory abnormalities, that would place the patient at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study - No known hypersensitivity to thalidomide or lenalidomide - No history of erythema nodosum characterized by a desquamating rash while taking thalidomide or similar drugs - No history of any other cancer except non-melanoma skin cancer or carcinoma in-situ of the cervix or cancer for which the patient is in complete remission and off therapy for > 3 years - No cardiac arrest within the past 6 months - No known history of hepatitis B infection, positive hepatitis B surface antigen, or positive hepatitis C antibody - No other concurrent anti-cancer agents or treatments - More than 28 days since any prior experimental drug or therapy - Aspirin (81 or 325 mg) or warfarin sodium daily as prophylactic anticoagulation required - No prior lenalidomide


Study is Available At:


Original ID:

NCI-2011-02568


NCT ID:

NCT01271283


Secondary ID:

NCI-2011-02568


Study Acronym:


Brief Title:

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia


Official Title:

Lenalidomide for the Treatment of CLL Patients With High-Risk Disease


Overall Status:

Withdrawn


Study Phase:

Phase 2


Genders:

Both


Minimum Age:

18 Years


Maximum Age:

N/A


Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

National Cancer Institute (NCI)


Oversight Authority:

United States: Food and Drug Administration


Reasons Why Stopped:


Study Type:

Interventional


Study Design:

Allocation: Non-Randomized, Endpoint Classificatio


Number of Arms:

1


Number of Groups:

0


Total Enrollment:

0


Enrollment Type:

Actual


Overall Contact Information

Official Name:Asher Chanan-Khan
Principal Investigator
Roswell Park Cancer Institute

Study Dates

Start Date:December 2010
Completion Date:August 2011
Completion Type:Actual
Primary Completion Date:August 2011
Primary Completion Type:Actual
Verification Date:November 2011
Last Changed Date:June 3, 2015
First Received Date:January 5, 2011

Study Outcomes

Outcome Type:Primary Outcome
Measure:Time to progression
Time Frame:From the start of lenalidomide therapy to time of disease progression, assessed up to 24 months
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Maximal clinical response (complete and partial response)
Time Frame:Up to 24 months
Safety Issues:False
Description:Summarized by a sample proportion along with the exact 95% confidence interval. The time-to-progression will be graphically analyzed using standard Kaplan-Meier estimation.

Study Interventions

Intervention Type:Other
Name:Diagnostic Laboratory Biomarker Analysis
Description:Correlative studies
Arm Name:Arm I
Intervention Type:Drug
Name:Lenalidomide
Description:Given orally
Arm Name:Arm I
Other Name:CC-5013

Study Arms

Study Arm Type:Experimental
Arm Name:Arm I
Description:Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days for 8 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (by morphological criteria but have persistent minimal residual disease by molecular criteria) or partial response may continue treatment beyond 8 courses. Patients may undergo bone marrow, peripheral blood, and/or lymph node sample collection at baseline and periodically during study for c

Study Agencies

Agency Class:NIH
Agency Type:Lead Sponsor
Agency Name:National Cancer Institute (NCI)

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


This study is not currently recruiting Study Participants. The form below is not enabled.